Information  X 
Enter a valid email address

Futura Medical PLC Ord 0.2P (FUM)

Related News

30-Apr-2021 02:57 PM

Futura Medical Receives Approval from EU Notified Body for MED3000

Pharmaceutical company Futura has announced that it has now received its MDR EU Quality Management Certificate for placing on the market of a Class II(b) medical device known as MED3000. MED3000, is the first clinically proven, pan-European topical treat
14-Apr-2021 10:10 AM

Futura Medical narrows annual losses on lower R&D spend

Pharmaceutical company Futura Medical reported narrower losses as research and development spend fell sharply. For the year ended 31 December 2020, pre-tax losses narrowed to £2.9 million from £11.1 million. Research and development costs
16-Sep-2020 07:58 AM

Futura Medical narrows losses in H1 on lower costs

Pharmaceutical company Futura Medical narrowed first-half losses on lower research and development costs. For the six months ended 30 June 2020, pre-tax losses narrowed to £1.39m from £5.26m on-year as research and development costs fell to &
24-Jun-2020 08:17 AM

Futura Medical says regulatory submissions for erectile dysfunction treatment remain on track

Pharmaceutical company Futura Medical said the impact of Covid-19 had been 'limited' to date and said it had continued to make 'good progress' on regulatory submissions for its erectile dysfunction treatment in both Europe and the US.
11-Sep-2019 08:24 AM

Futura Medical losses more than doubled amid a jump in R&D spend

Pharmaceutical company Futura Medical said first-half losses more than doubled thanks to a jump in research and development costs. For the six months ended 30 June 2019, pre-tax losses swelled to £5.3m from £2.5m a year earlier, with resear
17-Jun-2019 10:40 AM

Broker Forecast - Liberum Capital issues a broker note on Futura Medical PLC

Liberum Capital today initiates coverage of Futura Medical PLC (LON:FUM) with a buy investment rating and price target of 60p. Story provided by Broker Forecasts data provided by
14-Mar-2018 02:12 PM

Futura Medical losses deepen on higher R&D spend

Futura Medical, which makes erection-stimulating condoms, said annual losses widened, largely owing to higher R&D costs. The company booked a pre-tax loss of £4.8m, compared to a £4.5m loss in 2016. Its 'erectogenic' condom was suc
20-Feb-2018 09:53 AM

Futura Medical appoints Angela Hildreth as Finance Director after Derek Martin resigns

Futura Medical announced Tuesday that Derek Martin, the company's Finance Director, has resigned. Angela Hildreth will join the company in the role of Finance Director, Chief Operating Officer and Board Director. James Barder, Futura's Chie
04-Jan-2018 08:27 AM

Futura reports publication of positive MED2002 data

Futura Medical has announced the publication of positive data from its phase II clinical trial of MED2002 in erectile dysfunction in the peer-reviewed Journal of Sexual Medicine. The article is available at this link:
29-Nov-2017 09:08 AM

Recruitment starts for PK study, says Futura

Futura Medical has announced that recruitment has started for the company's pharmacokinetic study of MED2002, its novel gel for the treatment of erectile dysfunction. It said data from the PK study in 40 healthy subjects, which represented the init
16-Oct-2017 08:17 AM

Futura reports further positive data on MED2002

Futura Medical has recently completed primary market research which indicated that more than 60% of physicians in the US considered that MED2002, the company's novel gel for erectile dysfunction, was an improvement over current ED therapies. Futura
12-Sep-2017 08:20 AM

Futura net losses narrow

Futura Medical's first half net losses narrowed to £1.60m - down from £1.89m a year ago. It said this reflected the planned reduction in R&D expenditure in preparation for the MED clinical programme commencing in H2. The group had cash
14-Jun-2017 09:44 AM

Futura Medical making good progress

Futura Medical has made good progress, especially across its sexual health products, and looks forward to the year ahead with confidence, shareholders at the annual general meeting today will be told. Chairman John Clarke will say: "The development
06-Mar-2017 08:11 AM

Futura files new patent as research confirms $1bn potential

Futura Medical has filed a new formulation patent for its novel topical gel for the treatment of erectile dysfunction and reported that a validated market research model had confirmed the breakthrough potential of the gel as an over-the-counter product
23-Jan-2017 01:10 PM

Futura Medical schedules FY results

Futura Medical, the innovative healthcare company focused on advanced transdermal technology, will announce its preliminary results for the year ended 31 December on 23 March. At 1:10pm: (LON:FUM) Futura Medical PLC share price was 0p at 56.75p Story
10-Jan-2017 07:32 AM

Futura inks UK licensing agreement in pain relief

Futura Medical has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG, the international healthcare group, for the commercialisation of TPR100, the company's novel diclofenac gel for pain relief. The licensing agreement wa
05-Jan-2017 07:41 AM

Futura's CSD500 condom launched in Saudi Arabia

Futura Medical has announced the launch of CSD500, its novel erectogenic condom, in Saudi Arabia by Kabey Pharmaceuticals, the company's distribution partner for key territories in the Middle East and North Africa. Kabey anticipates further launches
16-Nov-2016 09:14 AM

Futura updates on clinical study

Futura Medical has announced the outcome of the detailed analysis of the results of the recent breakthrough clinical study of MED2002, its topical gel for erectile dysfunction, and outlined the company's strategy for the further development of the pr
13-Sep-2016 09:19 AM

Futura losses narrow

Futura Medical posts a net loss of £1.89 million for the six months to the end of June - down from a net loss £2.47 million a year ago and reflecting planned reduction in research and development expenditure. Revenues rose to £66,900 -
07-Sep-2016 09:05 AM

Futura gel achieves primary endpoint in study

Futura Medical has announced headline results from its pivotal efficacy study of MED2002, the company's novel gel for the treatment of erectile dysfunction. The results of the study show that MED2002 has achieved its primary endpoint and successful
22-Jun-2016 08:47 AM

Futura Medical resolutions passed at AGM

Futura Medical has confirmed that all resolutions proposed at its annual general meeting today were passed. At 8:47am: (LON:FUM) Futura Medical PLC share price was 0p at 24.5p Story provided by
21-Jun-2016 07:17 AM

Futura progress

Futura Medical is very pleased with recent progress in the commercialisation of its product pipeline, shareholders at the annual general meeting today will be told. Chairman John Clarke will say: ""On CSD500, our novel erectogenic condom, we co
26-Apr-2016 11:54 AM

Futura Medical confirms date of AGM

Futura Medical has announced that the Company's Annual General Meeting will be held on 21 June 2016. At 11:53am: (LON:FUM) Futura Medical PLC share price was -3p at 16.5p Story provided by
04-Jan-2016 01:22 PM

Futura issues shares to non-execs

Futura Medical has issued 69,718 new ordinary shares to its non-executive directors who receive around 30% of their remuneration in shares. These were issued at 35.50 pence per share - the average closing mid-price of the last 10 trading days of 2014, as
16-Dec-2015 09:47 AM

Futura extends shelf life of CSD500

Futura Medical has achieved a significantly extended shelf for its novel condom CSD500 compared with the currently approved shelf life of one year. The extended shelf life has been achieved using a modified manufacturing process as outlined in the compa
Top categories
Company finder

a d v e r t i s e m e n t